Bellus Health

About Us

Our Company

Our Company

BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. The Company’s product candidate, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus. BLU-5937 is a highly selective P2X3 inhibitor that has the potential to be a differentiated treatment option for patients that suffer from either condition. The Company is exploring how P2X3 activation contributes to irritation and pain, and whether inhibition of P2X3 receptors can help treat other afferent hypersensitization-related disorders.

Management Team

Roberto Bellini

Roberto Bellini

President and Chief
Executive Officer

Read More
Dr. Catherine Bonuccelli, MD

Dr. Catherine Bonuccelli, MD

Chief Medical Officer

Read More
Dr. Denis Garceau

Dr. Denis Garceau

Senior Vice President,
Drug Development

Read More
François Desjardins

François Desjardins

Vice President,
Finance

Read More
Tony Matzouranis

Tony Matzouranis

Vice President,
Business Development

Read More

Board of Directors

Dr. Francesco Bellini

Chair

Read More

Roberto Bellini

Read More

Dr. Youssef L. Bennani

Read More

Franklin M. Berger

Read More

Dr. Clarissa Desjardins

Read More

Chau Q. Khuong

Read More

Pierre Larochelle

Read More

Joseph Rus

Read More

Chronic Cough
Clinical Advisory Board

Dr. Jacky Smith, MB,
ChB, FRCP, PhD

Chair

Read More

Dr. Alan Goldsobel, MD

Read More

Dr. James Hull, BSc, MBBS,
FRCP, PhD, FACSM

Read More

Dr. Lorcan McGarvey,
MD, FRCP

Read More

Dr. Alyn Morice, MD

Read More

Dr. Mandel Sher, MD

Read More

Chronic Pruritus
Clinical Advisory Board

Prof. Gil Yosipovitch, MD, FAAD

Read More

Prof. Sonja Ständer, MD

Read More

Dr. Timothy Berger, MD

Read More

Dr. Robert Bissonnette, MD

Read More

Dr. Ethan Lerner, MD, PhD

Read More